miRNA Signature for Glioblastoma Subtyping

Glioblastoma (GBM) is the most malignant IV grade [according to The World Health Organization (WHO)] primary central nervous system tumour with a particularly poor outcome. Median survival without treatment is approximately a year, with radiotherapy and chemotherapy 5-year survival rates are 60% to 80%.

Author(s): Indre Valiulyte, Ruta Urbanaviciute

Abstract | Full-Text | PDF

Share This Article